<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Congenital melanocytic nevi</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Congenital melanocytic nevi</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Congenital melanocytic nevi</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Raegan Hunt, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julie V Schaffer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean L Bolognia, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hensin Tsao, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1574245489"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Congenital melanocytic nevi (CMN) are classically defined as melanocytic nevi present at birth or within the first few months of life. CMN and speckled lentiginous nevi (a subtype of CMN) will be discussed below. Acquired melanocytic nevi and other benign pigmented skin lesions are discussed separately. Atypical nevi are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4846.html" rel="external">"Acquired melanocytic nevi (moles)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5560.html" rel="external">"Benign pigmented skin lesions other than melanocytic nevi (moles)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13519.html" rel="external">"Atypical (dysplastic) nevi"</a>.)</p><p></p><p class="headingAnchor" id="H82850113"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>In prospective studies conducted in the United States, Mexico, China, Finland, Australia, and Japan, 1 to 3 percent of newborns had pigmented lesions that were clinically compatible with a diagnosis of CMN [<a href="#rid1">1</a>]. Large or giant CMN occur in approximately 1 in 20,000 births [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>CMN are hamartomas composed primarily of clonal proliferations of benign melanocytes that arise during embryogenesis [<a href="#rid3">3,4</a>]. Somatic <em>BRAF</em> V600E mutations have been found in a high proportion of small CMN as well as in acquired melanocytic nevi and cutaneous melanomas [<a href="#rid5">5,6</a>]. In contrast, 70 to 95 percent of large and giant CMN harbor somatic gain-of-function mutations in <em>NRAS</em> [<a href="#rid7">7,8</a>].</p><p>In patients with neurocutaneous melanocytosis (see <a class="local">'Neurocutaneous melanosis'</a> below), the same <em>NRAS</em> mutations have been found in multiple CMN and affected areas of melanocytic proliferation in the central nervous system [<a href="#rid9">9</a>]. Activating mutations of <em>BRAF</em> or <em>NRAS</em> result in cellular proliferation via increased signaling through several pathways, in particular mitogen-activated protein kinase (MAPK).</p><p class="headingAnchor" id="H1037857150"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>CMN lesions are categorized into subgroups based on the largest diameter that the nevus is projected to attain by adulthood [<a href="#rid10">10</a>] (see <a class="local">'Projected estimate of adult size'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital melanocytic nevi categories</strong> – CMN categories include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Small</strong> – &lt;1.5 cm  (<a class="graphic graphic_picture graphicRef74734" href="/d/graphic/74734.html" rel="external">picture 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medium-sized</strong> – M1 1.5 to 10 cm; M2 10 to 20 cm  (<a class="graphic graphic_picture graphicRef62970" href="/d/graphic/62970.html" rel="external">picture 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Large</strong> – L1 &gt;20 to 30 cm; L2 &gt;30 to 40 cm  (<a class="graphic graphic_picture graphicRef50057" href="/d/graphic/50057.html" rel="external">picture 3</a>). In a neonate, large CMN are &gt;9 cm on the head or &gt;6 cm on the body.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Giant</strong> – G1 &gt;40 to 60 cm; G2 &gt;60 cm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Satellite nevi</strong> – Large and giant CMN are further categorized by the number of satellite lesions present, as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>S – 0</p><p class="bulletIndent2"><span class="glyph">•</span>S1 – &lt;20</p><p class="bulletIndent2"><span class="glyph">•</span>S2 – 20 to 50</p><p class="bulletIndent2"><span class="glyph">•</span>S3 – &gt;50</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional features</strong> – Color heterogeneity, surface rugosity, the presence of dermal or subcutaneous nodules, and hypertrichosis can each be graded from 0 (none) to 2 (marked).</p><p></p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H2884667433"><span class="h2">General features</span><span class="headingEndMark"> — </span>CMN are generally present at birth or within the first few months of life. Small melanocytic nevi that become apparent during early childhood (especially between three months and two years of age) often have clinical and histologic features identical to those of "true" CMN and have been referred to as "tardive CMN," "early-onset nevi," and "congenital nevus-like nevi" [<a href="#rid11">11</a>].</p><p>Most CMN are small or medium-sized and solitary. The color ranges from tan to black or blue-black, and the borders are often geographic and irregular. Many, but not all, CMN have an increased density of dark, coarse (terminal) hairs, and the overlying hypertrichosis may develop over years.</p><p>Large CMN are frequently accompanied by multiple smaller, widely disseminated "satellite" nevi  (<a class="graphic graphic_picture graphicRef50057" href="/d/graphic/50057.html" rel="external">picture 3</a>). For large and giant nevi, the number of "satellite nevi" surrounding the nevus helps inform evaluation and monitoring for these patients. </p><p class="headingAnchor" id="H3771418425"><span class="h2">Anatomic distribution</span><span class="headingEndMark"> — </span>CMN can occur in any cutaneous area of the body. Because of their distribution, giant CMN are sometimes referred to as "garment" or "bathing trunk" nevi. Most giant CMN can be categorized into one of six anatomical distributions, termed the "<strong>six Bs</strong>" [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bolero</strong> – Upper back and neck</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Back</strong> – Central back, spares buttocks and shoulders</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bathing trunk</strong> – Mainly genital area and buttocks, does not extend to shoulders or neck</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breast/belly</strong> – Localized to breast and/or abdomen</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Body extremity</strong> – Only on extremity, spares genitals or shoulders</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Body</strong> – Involves most of body, overlap of bolero and bathing trunk</p><p></p><p class="headingAnchor" id="H1345827799"><span class="h2">Projected estimate of adult size</span><span class="headingEndMark"> — </span>CMN grow proportionately with the child's growth. To project an estimated adult CMN size, the following factors are multiplied by the greatest length of the CMN as measured in the infant: 1.7-fold on the head, 3.3-fold on the lower extremities, and 2.8-fold on the trunk and upper extremities.</p><p class="headingAnchor" id="H255866520"><span class="h1">DERMOSCOPIC FEATURES</span><span class="headingEndMark"> — </span>The main dermoscopic features seen in CMN, as well as in acquired melanocytic nevi, are pigment network; aggregated globules; and/or diffuse, homogeneous, brown pigmentation  (<a class="graphic graphic_figure graphicRef75995" href="/d/graphic/75995.html" rel="external">figure 1</a>) [<a href="#rid13">13</a>]. Common dermoscopic patterns seen in CMN are reticular, globular/cobblestoning, homogenous, and a mixture of these (ie, multicomponent) [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/13521.html" rel="external">"Overview of dermoscopy"</a> and  <a class="medical medical_review" href="/d/html/13522.html" rel="external">"Dermoscopic evaluation of skin lesions"</a>.)</p><p>However, CMN may exhibit exaggerated dermoscopic features compared with acquired melanocytic nevi, such as perifollicular hypopigmentation  (<a class="graphic graphic_picture graphicRef97248" href="/d/graphic/97248.html" rel="external">picture 4</a>); skin furrow hyperpigmentation; and prominent, follicular structures [<a href="#rid15">15,16</a>]. Additional features include hypertrichosis  (<a class="graphic graphic_picture graphicRef97249" href="/d/graphic/97249.html" rel="external">picture 5</a>), perifollicular pigment changes  (<a class="graphic graphic_picture graphicRef97251" href="/d/graphic/97251.html" rel="external">picture 6</a>), target globules  (<a class="graphic graphic_picture graphicRef97250" href="/d/graphic/97250.html" rel="external">picture 7</a>), focal areas of hypopigmentation, and network thickening  (<a class="graphic graphic_picture graphicRef97247" href="/d/graphic/97247.html" rel="external">picture 8</a>). Some authors have noted that a target network with dots, globules, or blood vessels  (<a class="graphic graphic_picture graphicRef97252" href="/d/graphic/97252.html" rel="external">picture 9</a>) is a more distinctive feature of CMN [<a href="#rid16">16</a>].</p><p>Dermoscopic features detected in CMN of the palms and soles include the parallel furrow pattern, which is also common in acquired acral nevi  (<a class="graphic graphic_picture graphicRef89403" href="/d/graphic/89403.html" rel="external">picture 10</a>) [<a href="#rid17">17</a>]. A more prominent crista dotted pattern  (<a class="graphic graphic_picture graphicRef89466" href="/d/graphic/89466.html" rel="external">picture 11</a>) or peas-in-a-pod pattern  (<a class="graphic graphic_picture graphicRef89467" href="/d/graphic/89467.html" rel="external">picture 12</a>) may also be seen, reflecting an increased number of nevus cell nests around distal eccrine ducts. (See  <a class="medical medical_review" href="/d/html/16551.html" rel="external">"Dermoscopy of pigmented lesions of the palms and soles"</a>.)</p><p class="headingAnchor" id="H581190556"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>Melanocytic nevi (moles) represent benign proliferations of a type of melanocyte known as a "nevus cell." The two major differences between ordinary melanocytes that reside in the basal layer of the epidermis and nevus cells are:</p><p class="bulletIndent1"><span class="glyph">●</span>Nevus cells cluster as nests within the lower epidermis and/or dermis, whereas epidermal melanocytes are evenly dispersed as single units.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nevus cells do not have dendritic processes (with the exception of nevus cells within blue nevi).</p><p></p><p>Both melanocytes and nevus cells produce the pigment melanin. In contrast to acquired melanocytic nevi, CMN tend to extend deeper into the dermis and subcutaneous tissues [<a href="#rid18">18</a>]. Melanocytes in CMN more often track along or within neurovascular and adnexal structures (eg, hair follicles, sebaceous glands, eccrine ducts) or are located between collagen bundles in a single-file array [<a href="#rid19">19-21</a>].</p><p class="headingAnchor" id="H57183984"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of a medium-sized, large, or giant CMN is usually straightforward, based upon the clinical appearance and a history of presence since birth or early infancy. Small congenital nevi may be difficult to distinguish from acquired nevi if history is uncertain. However, dermoscopic examination may be helpful in differentiating small CMN from atypical acquired nevi. (See  <a class="medical medical_review" href="/d/html/13522.html" rel="external">"Dermoscopic evaluation of skin lesions"</a> and  <a class="medical medical_review" href="/d/html/13519.html" rel="external">"Atypical (dysplastic) nevi"</a>.)</p><p class="headingAnchor" id="H4091712254"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The major entities in the differential diagnosis of a small or medium-sized CMN are a smooth muscle hamartoma and mastocytoma. The presence of a pseudo-Darier sign (surface induration occurring due to smooth muscle-based piloerection upon stroking lesion) or a Darier sign (wheal and flare reaction with erythema and edema due to mast cell degranulation upon stroking lesion  (<a class="graphic graphic_picture graphicRef139006" href="/d/graphic/139006.html" rel="external">picture 13</a>)) can help distinguish these entities, respectively. Dermoscopy and/or biopsy may be helpful if the clinical diagnosis is unclear. (See  <a class="medical medical_review" href="/d/html/4784.html" rel="external">"Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p>The differential diagnosis of medium-sized or large CMN may include a plexiform neurofibroma. A plexiform neurofibroma is favored if the lesion has a "bag of worms" texture on palpation or if there are other findings suggestive of neurofibromatosis type 1. (See  <a class="medical medical_review" href="/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">NATURAL HISTORY</span></p><p class="headingAnchor" id="H3961285545"><span class="h2">Overview</span><span class="headingEndMark"> — </span>CMN enlarge in proportion to the child's growth and tend to grow more rapidly during early infancy [<a href="#rid22">22</a>]. In addition to increasing in size, CMN undergo other age-related changes in appearance. They often begin as flat, evenly pigmented patches that later become elevated with a pebbly  (<a class="graphic graphic_picture graphicRef62970" href="/d/graphic/62970.html" rel="external">picture 2</a>), verrucous, or cerebriform surface and darker, lighter, mottled, or speckled pigmentation [<a href="#rid23">23</a>]. Dermal melanocytes within CMN may undergo peripheral nerve sheath differentiation or neurotization, which results in the development of soft nodules and large, plexiform, neurofibroma-like plaques [<a href="#rid4">4</a>].</p><p>CMN located on the scalp may have a particular tendency to gradually lighten and regress over time [<a href="#rid24">24</a>]. The halo phenomenon (ie, the development of a depigmented halo around the nevus), which is more commonly observed with acquired melanocytic nevi but does occur in CMN, represents another means by which CMN in any site can regress  (<a class="graphic graphic_picture graphicRef139008" href="/d/graphic/139008.html" rel="external">picture 14</a>) [<a href="#rid25">25</a>]. In some cases, the development of halo nevus depigmentation is preceded by dermatitis on and/or around the nevus [<a href="#rid26">26</a>].</p><p>During the neonatal period, transient erosions or ulcerations may arise at sites of obvious friction within medium-sized and large CMN as a reflection of increased skin fragility. (See <a class="local">'Management'</a> below.)</p><p class="headingAnchor" id="H765115"><span class="h2">Proliferative nodules</span><span class="headingEndMark"> — </span>Proliferative nodules are benign melanocytic proliferations that occasionally develop within large or giant CMN [<a href="#rid27">27</a>]. They may be congenital or appear during infancy or childhood.</p><p>Because of their rapid growth and clinical characteristics (eg, firmness or ulceration), biopsy is recommended to exclude melanoma (see <a class="local">'Monitoring for melanoma'</a> below). However, the histopathologic distinction of proliferative nodules from melanoma may prove difficult because of the presence of large, atypical melanocytes and mitoses  (<a class="graphic graphic_picture graphicRef94602" href="/d/graphic/94602.html" rel="external">picture 15</a>). This is a situation where evaluation by experienced dermatopathologists is essential. Techniques such as comparative genomic hybridization can help to distinguish proliferative nodules (usually having no chromosomal aberrations or only whole chromosomal copy number aberration) from melanoma (typically demonstrating gains/losses of chromosomal fragments) [<a href="#rid27">27,28</a>]. Mass spectroscopy imaging proteomic analysis may also help differentiate proliferative nodules from melanoma [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma", section on 'Genetic and molecular characterization of melanoma'</a>.)</p><p class="headingAnchor" id="H765200"><span class="h1">COMPLICATIONS</span></p><p class="headingAnchor" id="H7"><span class="h2">Risk of melanoma</span><span class="headingEndMark"> — </span>Individuals with CMN, and especially those with large or giant CMN, have an increased risk of developing a melanoma [<a href="#rid29">29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Small/medium-sized congenital melanocytic nevi</strong> – The risk of melanoma arising within small and medium-sized CMN is thought to be less than 1 percent over a lifetime [<a href="#rid3">3</a>]. In small and medium-sized CMN, melanoma most often occurs after puberty and tends to arise at the dermal-epidermal junction, in contrast to the earlier onset and deeper origin of many melanomas arising within large or giant CMN.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Large/giant congenital melanocytic nevi</strong> – For patients with large or giant CMN, the risk of developing melanoma (cutaneous or extracutaneous) is estimated to be approximately 2 to 5 percent over a lifetime, with approximately one-half occurring by five years of age [<a href="#rid30">30,31</a>]. Patients with a "giant" (&gt;40 cm) CMN in a posterior axial location with numerous satellite nevi have the greatest risk of developing melanoma. In a cohort study including 349 children with CMN (145 with large CMN), 5 children (3.4 percent) developed a fatal melanoma at one to seven years of age [<a href="#rid32">32</a>]. In all cases, the projected adult size of the nevus was &gt;60 cm, and satellite nevi were present at birth. Melanomas arise less often within CMN restricted to the head or an extremity. No documented primary cutaneous melanomas developing within satellite nevi have been reported.</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Neurocutaneous melanosis</span><span class="headingEndMark"> — </span>Patients with CMN may rarely develop neurocutaneous melanosis, a proliferation of melanocytes in the central nervous system as well as the skin. Neurocutaneous melanosis encompasses both leptomeningeal melanosis and central nervous system melanosis [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/5202.html" rel="external">"Uncommon brain tumors", section on 'Primary melanocytic lesions'</a>.)</p><p>Neurocutaneous melanosis may be asymptomatic (noted on screening magnetic resonance imaging [MRI]) or symptomatic [<a href="#rid34">34</a>]. Symptomatic neurocutaneous melanosis is associated with a poor prognosis, with a high mortality rate in the first few years of life [<a href="#rid35">35,36</a>].</p><p class="headingAnchor" id="H973716871"><span class="h3">Risk factors</span><span class="headingEndMark"> — </span>Risk factors for neurocutaneous melanosis include [<a href="#rid34">34,37-40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A large CMN, especially if the predicted final size is &gt;40 cm</p><p class="bulletIndent1"><span class="glyph">●</span>Numerous satellite nevi</p><p class="bulletIndent1"><span class="glyph">●</span>More than three medium-sized CMN (especially if many)</p><p></p><p>In a study of 379 patients with large CMN, of whom 26 (7 percent) had been diagnosed with neurocutaneous melanosis, those with &gt;20 satellites had a fivefold increased risk for neurocutaneous melanosis compared with those with ≤20 satellites [<a href="#rid40">40</a>]. Neurocutaneous melanosis can also develop in patients with nevus of Ota. (See  <a class="medical medical_review" href="/d/html/5560.html" rel="external">"Benign pigmented skin lesions other than melanocytic nevi (moles)", section on 'Nevus of Ota'</a>.)</p><p class="headingAnchor" id="H3125015138"><span class="h3">Clinical manifestations</span><span class="headingEndMark"> — </span>Symptomatic neurocutaneous melanosis develops in approximately 3 to 10 percent of infants and children with high-risk CMN [<a href="#rid38">38</a>]. Clinical presentation occurs at a median age of two years, and prognosis is often poor even in the absence of malignancy [<a href="#rid41">41</a>]. Neurologic manifestations (eg, hydrocephalus, seizures) may result from intracranial hemorrhage, impaired cerebrospinal fluid circulation, spinal cord compression, or malignant transformation of the melanocytes [<a href="#rid3">3,42</a>].</p><p>Developmental delay and/or seizures have been reported in up to 15 to 25 percent of children with large or multiple CMN (some of whom did not have MRI evidence of neurocutaneous melanosis) [<a href="#rid32">32,38,43</a>].</p><p>Structural abnormalities of the central nervous system (eg, Dandy-Walker malformation/posterior fossa cysts), defects of the vertebrae or skull, and intraspinal lipomas occasionally occur in association with neurocutaneous melanosis [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/d/html/6745.html" rel="external">"Prenatal diagnosis of CNS anomalies other than neural tube defects and ventriculomegaly", section on 'Dandy-Walker malformation'</a>.)</p><p class="headingAnchor" id="H3807643963"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>Neurocutaneous melanosis is best detected by MRI with gadolinium contrast [<a href="#rid34">34</a>]. For very young infants, it may be possible to obtain initial high-quality MRI images without general anesthesia using "feed and wrap" techniques that allow a swaddled infant to sleep during the MRI imaging procedure [<a href="#rid44">44</a>].</p><p>MRI of the brain and spine should be performed in any high-risk patient exhibiting neurologic symptoms. However, we also suggest that asymptomatic, high-risk patients be screened for neurocutaneous melanosis with gadolinium-enhanced MRI of the brain and spine (ideally during the first six months of life) before myelination, which may obscure evidence of melanosis [<a href="#rid41">41</a>].</p><p>Asymptomatic neurocutaneous melanosis is detected by MRI in 5 to 25 percent of infants and children with high-risk CMN [<a href="#rid4">4,45</a>]. In a five-year, follow-up study, only 1 of 10 patients with MRI findings suggestive of central nervous system melanosis progressed to develop neurologic symptoms [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H1969554715"><span class="h3">Referral</span><span class="headingEndMark"> — </span>Patients with high-risk CMN and neurologic symptoms or abnormal MRI findings should be referred to a pediatric neurologist for evaluation and monitoring. If the diagnosis of neurocutaneous melanosis is confirmed, repeat MRIs should be performed with the frequency guided by the degree of involvement and clinical findings [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Other malignancies</span><span class="headingEndMark"> — </span>Other malignancies, such as rhabdomyosarcoma, liposarcoma, and malignant peripheral nerve sheath tumors, have been reported in the setting of large CMN [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H10"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The available evidence on treatment of CMN is limited to case series and small, observational studies [<a href="#rid47">47,48</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Small/medium-sized congenital melanocytic nevi</span><span class="headingEndMark"> — </span>Small and medium-sized CMN are generally considered nonproblematic. These lesions are managed on an individual basis depending on factors that affect ease of monitoring (eg, color, thickness/topography, and location), clinical history, parents' or caregivers' anxiety, and cosmetic concerns [<a href="#rid4">4</a>].</p><p>As an example, a multinodular, black CMN on the scalp that is partially obscured by dense hair growth would be difficult to follow clinically, whereas a thin, light brown lesion on the face would be relatively simple to observe. However, the latter might be removed for cosmetic reasons, and the former may spontaneously lighten during childhood:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical observation</strong> – Observation is an option for CMN of any size. Regular skin examination is most important after puberty, since the risk of melanoma arising within these lesions during childhood is extremely low. Baseline photographs can be helpful, and dermoscopy is a useful tool for assessing changes. (See  <a class="medical medical_review" href="/d/html/13522.html" rel="external">"Dermoscopic evaluation of skin lesions"</a>.)</p><p></p><p class="bulletIndent1">Patients and parents/caregivers should be instructed to perform home skin examinations, including palpation, of all nevi and to bring focal changes in color, border, or topography (eg, a red or black papule, nodule, or crust) or any new symptoms (eg, itching, burning, bleeding) to the clinician's attention. (See  <a class="medical medical_review" href="/d/html/4845.html" rel="external">"Screening for melanoma in adults and adolescents", section on 'Patient self-examination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical excision</strong> – In many cases, surgical removal of small or medium-sized CMN is desired to improve the esthetic appearance [<a href="#rid49">49</a>]. Careful consideration of the anatomic location and the potential cosmetic and functional impairment resulting from excision and scarring is mandatory. For small CMN, some experts suggest one-step excision with direct wound closure if feasible. Excision may be performed at any point in time [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laser therapy</strong> – Pigment-specific lasers (eg, 694 nm quality-switched [Q-switched] ruby laser, 755 nm Q-switched alexandrite laser) and ablative lasers (eg, 10,600 nm carbon dioxide [CO<sub>2</sub>] laser, 2940 nm erbium-doped yttrium aluminum garnet [Er:YAG] laser) have been used in small series of patients with small and medium-sized CMN with variable results [<a href="#rid50">50-52</a>]. Recurrence is common, and ablative lasers carry a risk for significant scarring. In one report, treatment with dual-wavelength copper vapor laser (511 and 578 nm wavelengths) demonstrated cosmetic improvement after two to three sessions in two adult patients with small CMN on the face [<a href="#rid53">53</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Large/giant congenital melanocytic nevi</span><span class="headingEndMark"> — </span>Given the relative rarity of large or giant CMN, there are no randomized trials evaluating the efficacy and outcomes of conservative or interventional approaches. The decision to treat and the possible surgical approaches should be discussed in a multidisciplinary team, including a pediatric dermatologist, plastic surgeon, and as needed, a neuroradiologist, neurologist, and oncologist [<a href="#rid54">54,55</a>]. A crucial point of the decision-making process, which should include parents and caregivers, is whether the lesion should be observed or treated surgically in the attempt to mitigate stigmatization and psychosocial consequences [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H2114091120"><span class="h3">Observation versus surgery</span><span class="headingEndMark"> — </span>In most cases, close clinical observation with no surgical removal of the lesion is a favored choice, but shared decision-making with parents or caregivers that focuses on achievable results with either approach is paramount [<a href="#rid48">48</a>].</p><p>In general, early surgical treatment of CMN, including dermabrasion and curettage in the neonatal period, has fallen out of favor. Close clinical observation with no surgical removal of the lesion is encouraged for large and giant CMN, unless worrisome clinical features suspicious of malignancy are present [<a href="#rid48">48,55,56</a>].</p><p>Reasons for avoiding surgery include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>There is no evidence that surgical interventions for large CMN reduce the risk of melanoma compared with nonintervention. In a series of 250 patients treated with excision, dermabrasion, laser, or combination treatment, two patients developed melanoma over a median follow-up period of nine years [<a href="#rid55">55</a>]. There are reports of melanoma occurring in adult patients who underwent dermabrasion or surgical excision of CMN during childhood [<a href="#rid57">57,58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elimination of every nevus cell may be impossible because of the large area of skin affected, anatomic site (eg, distal extremity, periocular area, genitalia), and involvement of deeper structures (eg, fat, fascia, muscle). Even theoretically complete surgical excision cannot eliminate future risk of melanoma, as some melanomas may develop in the central nervous system or retroperitoneum in these patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although the short-term cosmetic outcomes of dermabrasion or curettage in the neonatal period seem favorable, repigmentation and extensive scarring occur in most cases [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many untreated CMN spontaneously lighten over time [<a href="#rid55">55</a>].</p><p></p><p class="headingAnchor" id="H4233632004"><span class="h3">Surgical approaches</span><span class="headingEndMark"> — </span>For large CMN for which surgical excision is advised or feasible, some experts suggest serial excisions at four- to eight-month intervals, starting at the age of six months, as the preferred treatment approach [<a href="#rid49">49</a>]. Advantages of serial excision include a single, linear scar (when the size of the nevus allows) without the need for skin grafts or large flaps.</p><p>Full-thickness skin grafts or skin expansion and advancement flaps may be needed for patients requiring multiple partial excisions. However, skin expansion is associated with a high rate of complications (eg, hematoma, infection, flap necrosis) requiring additional reconstruction [<a href="#rid59">59,60</a>].</p><p>Other surgical approaches, including curettage and dermabrasion in the neonatal period, are associated with adverse outcomes, including scarring and frequent pigment recurrence [<a href="#rid48">48</a>].</p><p>Regardless of the treatments employed, patients with large or giant CMN who have undergone surgical excision should be monitored for melanoma development with periodic skin and general physical examinations. Palpation of the residual nevus or scar areas is essential for the detection of focal indurations. Firm nodules or indurated areas should be biopsied and sent for histopathologic examination. (See <a class="local">'Monitoring for melanoma'</a> below.)</p><p>Even a theoretically complete removal of a large CMN does not eliminate the risk of melanoma, since melanoma of the central nervous system and other visceral primary sites (eg, the retroperitoneum) may still occur [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H3679606186"><span class="h2">Monitoring for melanoma</span><span class="headingEndMark"> — </span>Regular follow-up visits early in life with skin photography, when possible, are helpful to identify changes in CMN. Particularly in large or giant CMN, cutaneous melanomas can arise subepidermally, making early recognition difficult.</p><p>Palpation of the entire nevus surface for the detection of focal induration is an important part of the physical examination to try to detect deep nodules. In some patients with large or giant CMN, the site of the primary melanoma is the central nervous system or retroperitoneum, whereas others have no identifiable primary site.</p><p>Biopsy is recommended if the following changes are noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Firm or rapidly growing nodules</p><p class="bulletIndent1"><span class="glyph">●</span>Ulcerated nodules</p><p class="bulletIndent1"><span class="glyph">●</span>Amelanotic, atypically pigmented, or friable nodules</p><p class="bulletIndent1"><span class="glyph">●</span>Focally painful or persistently itchy lesions</p><p class="bulletIndent1"><span class="glyph">●</span>Irregular lesions, especially when crossing the border of the large of giant CMN or nevus excision scar</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Surveillance for neurocutaneous melanosis</span><span class="headingEndMark"> — </span>Patients with a large or giant CMN plus multiple (especially &gt;20) satellite nevi or with multiple medium-sized CMN are at risk for neurocutaneous melanosis and should be followed with serial head circumference measurements, neurologic examinations, and developmental assessments [<a href="#rid3">3,38,40</a>]. This monitoring includes evaluation for signs and symptoms of increased intracranial pressure, mass lesions, and spinal cord compression [<a href="#rid3">3,40</a>].</p><p>Given the poor prognosis, aggressive surgical procedures for CMN removal in patients with symptomatic neurocutaneous melanosis should generally be avoided. However, neurocutaneous melanosis discovered on imaging in an asymptomatic patient does not necessarily preclude CMN excision surgery.</p><p class="headingAnchor" id="H14"><span class="h1">SPECKLED LENTIGINOUS NEVUS</span><span class="headingEndMark"> — </span>Speckled lentiginous nevus (or nevus spilus) is a hyperpigmented, macular, patch-type, tan or light brown patch that contains superimposed, darker brown macules and papules  (<a class="graphic graphic_picture graphicRef64780 graphicRef94650" href="/d/graphic/64780.html" rel="external">picture 16A-B</a>). The "background" tan patch (café-au-lait macule-like) of a speckled lentiginous nevus is usually noted at birth or soon after, with round, pigmented macules and thin papules appearing within the lesion over time.</p><p>The superimposed, pigmented macules and papules can range from lentigines; to junctional, compound, and intradermal nevi; Spitz nevi; and blue nevi. There are two distinct subtypes of speckled lentiginous nevus: those with only macular speckles and those with papular and macular speckles [<a href="#rid62">62</a>].</p><p>Several lines of evidence suggest that speckled lentiginous nevi, which have a prevalence of approximately 2 percent, represent a subtype of CMN [<a href="#rid63">63</a>]. Some speckled lentiginous nevi have patterns of distribution reflecting embryonic development (eg, block-like with a sharp demarcation at the midline or following the lines of Blaschko).</p><p>The risk of developing melanoma in speckled lentiginous nevus is thought to be similar to classic CMN of the same size range. Speckled lentiginous nevus should be followed clinically with periodic examinations and biopsy of suspicious areas. (See <a class="local">'Management'</a> above and  <a class="medical medical_review" href="/d/html/4844.html" rel="external">"Melanoma: Epidemiology and risk factors", section on 'Congenital nevi'</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and classification</strong> – Congenital melanocytic nevi (CMN) occur in 1 to 3 percent of newborn infants; large or giant CMN occur in approximately 1 in 20,000 births (see <a class="local">'Epidemiology'</a> above). Based on the largest diameter that the nevus is projected to attain by adulthood, CMN are classified as follows (see <a class="local">'Classification'</a> above and <a class="local">'Projected estimate of adult size'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Small – &lt;1.5 cm  (<a class="graphic graphic_picture graphicRef74734" href="/d/graphic/74734.html" rel="external">picture 1</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Medium-sized – M1 1.5 to 10 cm; M2 10 to 20 cm  (<a class="graphic graphic_picture graphicRef62970" href="/d/graphic/62970.html" rel="external">picture 2</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Large – L1 &gt;20 to 30 cm; L2 &gt;30 to 40 cm  (<a class="graphic graphic_picture graphicRef50057" href="/d/graphic/50057.html" rel="external">picture 3</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Giant – G1 &gt;40 to 60 cm; G2 &gt;60 cm </p><p></p><p class="bulletIndent1">In a neonate, large CMN are &gt;9 cm on the head or &gt;6 cm on the body.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The color of CMN ranges from tan to black, and the borders are often geographic and irregular. Many CMN have an increased density of dark, coarse hairs  (<a class="graphic graphic_picture graphicRef50057" href="/d/graphic/50057.html" rel="external">picture 3</a>). Giant CMN are sometimes referred to as "garment" nevi, including "bathing trunk" nevi  (<a class="graphic graphic_picture graphicRef50057" href="/d/graphic/50057.html" rel="external">picture 3</a>) and bolero nevi, and are frequently accompanied by multiple smaller, widely disseminated "satellite" nevi. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural history</strong> – CMN enlarge in proportion to the child's growth and undergo other age-related changes in pigmentation or surface characteristics. Many untreated CMN spontaneously lighten over time. Superimposed papules and nodules can develop, which occasionally require histologic examination to exclude the development of a cutaneous melanoma. (See <a class="local">'Natural history'</a> above and <a class="local">'Proliferative nodules'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of melanoma</strong> – The risk of melanoma developing within a CMN is correlated with the nevus size. For small and medium-sized CMN, the risk is controversial but thought to be less than 1 percent over a lifetime. For large and giant CMN, the risk of cutaneous or extracutaneous melanoma is estimated to be approximately 2 to 5 percent over a lifetime. (See <a class="local">'Risk of melanoma'</a> above and  <a class="medical medical_review" href="/d/html/4844.html" rel="external">"Melanoma: Epidemiology and risk factors", section on 'Congenital nevi'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of neurocutaneous melanosis</strong> – Patients with CMN may have proliferation of melanocytes in the central nervous system (neurocutaneous melanosis) as well as the skin. Patients with either a large CMN accompanied by satellite nevi or multiple medium-sized CMN (≥3, usually numerous) are at risk of neurocutaneous melanosis. Neurocutaneous melanosis can be asymptomatic or may present with neurologic symptoms, such as hydrocephalus and seizures. (See <a class="local">'Neurocutaneous melanosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Small/medium-sized congenital melanocytic nevi</strong> – Small and medium-sized CMN are managed on an individual basis depending upon ease of monitoring, clinical history, parents' or caregivers' anxiety, and cosmetic concerns. (See <a class="local">'Small/medium-sized congenital melanocytic nevi'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Large/giant congenital melanocytic nevi</strong> – For large or giant CMN, clinical observation is a reasonable choice in most cases. When possible, surgical excision of large areas of nevus may require serial excisions, with or without tissue expanders, skin grafts, or advancement flaps. The timing of surgery and the surgical techniques are based upon size, location, and anesthesia options. (See <a class="local">'Large/giant congenital melanocytic nevi'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surveillance for melanoma and neurocutaneous melanosis</strong> – Regular follow-up visits early in life with serial skin photography, when possible, are helpful to identify changes in CMN. A biopsy is warranted for any changes suspicious of melanoma (eg, a nodule that is growing rapidly or is ulcerated or amelanotic). Patients with large/giant CMN at risk for neurocutaneous melanosis should be screened with gadolinium-enhanced MRI of the brain and spine during the first six months of life. (See <a class="local">'Monitoring for melanoma'</a> above and <a class="local">'Surveillance for neurocutaneous melanosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kanada KN, Merin MR, Munden A, Friedlander SF. A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature. J Pediatr 2012; 161:240.</a></li><li><a class="nounderline abstract_t">Castilla EE, da Graça Dutra M, Orioli-Parreiras IM. Epidemiology of congenital pigmented naevi: I. Incidence rates and relative frequencies. Br J Dermatol 1981; 104:307.</a></li><li><a class="nounderline abstract_t">Tannous ZS, Mihm MC Jr, Sober AJ, Duncan LM. Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol 2005; 52:197.</a></li><li><a class="nounderline abstract_t">Price HN, Schaffer JV. Congenital melanocytic nevi-when to worry and how to treat: Facts and controversies. Clin Dermatol 2010; 28:293.</a></li><li><a class="nounderline abstract_t">Ichii-Nakato N, Takata M, Takayanagi S, et al. High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. J Invest Dermatol 2006; 126:2111.</a></li><li><a class="nounderline abstract_t">Wu J, Rosenbaum E, Begum S, Westra WH. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. Am J Dermatopathol 2007; 29:534.</a></li><li><a class="nounderline abstract_t">Dessars B, De Raeve LE, Morandini R, et al. Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis. J Invest Dermatol 2009; 129:139.</a></li><li><a class="nounderline abstract_t">Charbel C, Fontaine RH, Malouf GG, et al. NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi. J Invest Dermatol 2014; 134:1067.</a></li><li><a class="nounderline abstract_t">Kinsler VA, Thomas AC, Ishida M, et al. Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Invest Dermatol 2013; 133:2229.</a></li><li><a class="nounderline abstract_t">Krengel S, Scope A, Dusza SW, et al. New recommendations for the categorization of cutaneous features of congenital melanocytic nevi. J Am Acad Dermatol 2013; 68:441.</a></li><li><a class="nounderline abstract_t">Makkar HS, Frieden IJ. Congenital melanocytic nevi: an update for the pediatrician. Curr Opin Pediatr 2002; 14:397.</a></li><li><a class="nounderline abstract_t">Martins da Silva VP, Marghoob A, Pigem R, et al. Patterns of distribution of giant congenital melanocytic nevi (GCMN): The 6B rule. J Am Acad Dermatol 2017; 76:689.</a></li><li><a class="nounderline abstract_t">Haliasos EC, Kerner M, Jaimes N, et al. Dermoscopy for the pediatric dermatologist part III: dermoscopy of melanocytic lesions. Pediatr Dermatol 2013; 30:281.</a></li><li><a class="nounderline abstract_t">Changchien L, Dusza SW, Agero AL, et al. Age- and site-specific variation in the dermoscopic patterns of congenital melanocytic nevi: an aid to accurate classification and assessment of melanocytic nevi. Arch Dermatol 2007; 143:1007.</a></li><li><a class="nounderline abstract_t">Seidenari S, Pellacani G, Martella A, et al. Instrument-, age- and site-dependent variations of dermoscopic patterns of congenital melanocytic naevi: a multicentre study. Br J Dermatol 2006; 155:56.</a></li><li><a class="nounderline abstract_t">Ingordo V, Iannazzone SS, Cusano F, Naldi L. Dermoscopic features of congenital melanocytic nevus and Becker nevus in an adult male population: an analysis with a 10-fold magnification. Dermatology 2006; 212:354.</a></li><li><a class="nounderline abstract_t">Minagawa A, Koga H, Saida T. Dermoscopic characteristics of congenital melanocytic nevi affecting acral volar skin. Arch Dermatol 2011; 147:809.</a></li><li><a class="nounderline abstract_t">Mark GJ, Mihm MC, Liteplo MG, et al. Congenital melanocytic nevi of the small and garment type. Clinical, histologic, and ultrastructural studies. Hum Pathol 1973; 4:395.</a></li><li><a class="nounderline abstract_t">Precursors to malignant melanoma. National Institutes of Health Consensus Development Conference Statement, Oct. 24-26, 1983. J Am Acad Dermatol 1984; 10:683.</a></li><li class="breakAll">Rabinovitz HS, Barnhill RL. Benign melanocytic neoplasms. In: Dermatology, 3rd ed, Bolognia JL, Jorizzo JL, Schaffer JV (Eds), Elsevier-Saunders, 2012.</li><li><a class="nounderline abstract_t">Kokta V, Hung T, Al Dhaybi R, et al. High prevalence of angiotropism in congenital melanocytic nevi: an analysis of 53 cases. Am J Dermatopathol 2013; 35:180.</a></li><li><a class="nounderline abstract_t">Rhodes AR, Albert LS, Weinstock MA. Congenital nevomelanocytic nevi: proportionate area expansion during infancy and early childhood. J Am Acad Dermatol 1996; 34:51.</a></li><li><a class="nounderline abstract_t">Ruiz-Maldonado R, Tamayo L, Laterza AM, Durán C. Giant pigmented nevi: clinical, histopathologic, and therapeutic considerations. J Pediatr 1992; 120:906.</a></li><li><a class="nounderline abstract_t">Strauss RM, Newton Bishop JA. Spontaneous involution of congenital melanocytic nevi of the scalp. J Am Acad Dermatol 2008; 58:508.</a></li><li><a class="nounderline abstract_t">Mundinger GS. Images in clinical medicine. Halo phenomenon. N Engl J Med 2014; 370:262.</a></li><li><a class="nounderline abstract_t">Rolland S, Kokta V, Marcoux D. Meyerson phenomenon in children: observation in five cases of congenital melanocytic nevi. Pediatr Dermatol 2009; 26:292.</a></li><li><a class="nounderline abstract_t">Phadke PA, Rakheja D, Le LP, et al. Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases. Am J Surg Pathol 2011; 35:656.</a></li><li><a class="nounderline abstract_t">Lazova R, Yang Z, El Habr C, et al. Mass Spectrometry Imaging Can Distinguish on a Proteomic Level Between Proliferative Nodules Within a Benign Congenital Nevus and Malignant Melanoma. Am J Dermatopathol 2017; 39:689.</a></li><li><a class="nounderline abstract_t">Zaal LH, Mooi WJ, Klip H, van der Horst CM. Risk of malignant transformation of congenital melanocytic nevi: a retrospective nationwide study from The Netherlands. Plast Reconstr Surg 2005; 116:1902.</a></li><li><a class="nounderline abstract_t">Watt AJ, Kotsis SV, Chung KC. Risk of melanoma arising in large congenital melanocytic nevi: a systematic review. Plast Reconstr Surg 2004; 113:1968.</a></li><li><a class="nounderline abstract_t">Vourc'h-Jourdain M, Martin L, Barbarot S, aRED. Large congenital melanocytic nevi: therapeutic management and melanoma risk: a systematic review. J Am Acad Dermatol 2013; 68:493.</a></li><li><a class="nounderline abstract_t">Kinsler VA, Birley J, Atherton DJ. Great Ormond Street Hospital for Children Registry for congenital melanocytic naevi: prospective study 1988-2007. Part 1-epidemiology, phenotype and outcomes. Br J Dermatol 2009; 160:143.</a></li><li><a class="nounderline abstract_t">Foster RD, Williams ML, Barkovich AJ, et al. Giant congenital melanocytic nevi: the significance of neurocutaneous melanosis in neurologically asymptomatic children. Plast Reconstr Surg 2001; 107:933.</a></li><li><a class="nounderline abstract_t">Neale H, Plumptre I, Belazarian L, et al. Central nervous system magnetic resonance imaging abnormalities and neurologic outcomes in pediatric patients with congenital nevi: A 10-year multi-institutional retrospective study. J Am Acad Dermatol 2022; 87:1060.</a></li><li><a class="nounderline abstract_t">Alikhan A, Ibrahimi OA, Eisen DB. Congenital melanocytic nevi: where are we now? Part I. Clinical presentation, epidemiology, pathogenesis, histology, malignant transformation, and neurocutaneous melanosis. J Am Acad Dermatol 2012; 67:495.e1.</a></li><li><a class="nounderline abstract_t">Ramaswamy V, Delaney H, Haque S, et al. Spectrum of central nervous system abnormalities in neurocutaneous melanocytosis. Dev Med Child Neurol 2012; 54:563.</a></li><li><a class="nounderline abstract_t">DeDavid M, Orlow SJ, Provost N, et al. Neurocutaneous melanosis: clinical features of large congenital melanocytic nevi in patients with manifest central nervous system melanosis. J Am Acad Dermatol 1996; 35:529.</a></li><li><a class="nounderline abstract_t">Kinsler VA, Chong WK, Aylett SE, Atherton DJ. Complications of congenital melanocytic naevi in children: analysis of 16 years' experience and clinical practice. Br J Dermatol 2008; 159:907.</a></li><li><a class="nounderline abstract_t">Lovett A, Maari C, Decarie JC, et al. Large congenital melanocytic nevi and neurocutaneous melanocytosis: one pediatric center's experience. J Am Acad Dermatol 2009; 61:766.</a></li><li><a class="nounderline abstract_t">Marghoob AA, Dusza S, Oliveria S, Halpern AC. Number of satellite nevi as a correlate for neurocutaneous melanocytosis in patients with large congenital melanocytic nevi. Arch Dermatol 2004; 140:171.</a></li><li><a class="nounderline abstract_t">Schaffer JV, McNiff JM, Bolognia JL. Cerebral mass due to neurocutaneous melanosis: eight years later. Pediatr Dermatol 2001; 18:369.</a></li><li><a class="nounderline abstract_t">Di Rocco F, Sabatino G, Koutzoglou M, et al. Neurocutaneous melanosis. Childs Nerv Syst 2004; 20:23.</a></li><li><a class="nounderline abstract_t">Krengel S, Breuninger H, Beckwith M, Etchevers HC. Meeting report from the 2011 International Expert Meeting on Large Congenital Melanocytic Nevi and Neurocutaneous Melanocytosis, Tübingen. Pigment Cell Melanoma Res 2011; 24:E1.</a></li><li><a class="nounderline abstract_t">Antonov NK, Ruzal-Shapiro CB, Morel KD, et al. Feed and Wrap MRI Technique in Infants. Clin Pediatr (Phila) 2017; 56:1095.</a></li><li><a class="nounderline abstract_t">Agero AL, Benvenuto-Andrade C, Dusza SW, et al. Asymptomatic neurocutaneous melanocytosis in patients with large congenital melanocytic nevi: a study of cases from an Internet-based registry. J Am Acad Dermatol 2005; 53:959.</a></li><li><a class="nounderline abstract_t">Hoang MP, Sinkre P, Albores-Saavedra J. Rhabdomyosarcoma arising in a congenital melanocytic nevus. Am J Dermatopathol 2002; 24:26.</a></li><li><a class="nounderline abstract_t">Ibrahimi OA, Alikhan A, Eisen DB. Congenital melanocytic nevi: where are we now? Part II. Treatment options and approach to treatment. J Am Acad Dermatol 2012; 67:515.e1.</a></li><li><a class="nounderline abstract_t">Jahnke MN, O'Haver J, Gupta D, et al. Care of Congenital Melanocytic Nevi in Newborns and Infants: Review and Management Recommendations. Pediatrics 2021; 148.</a></li><li><a class="nounderline abstract_t">Ott H, Krengel S, Beck O, et al. Multidisciplinary long-term care and modern surgical treatment of congenital melanocytic nevi - recommendations by the CMN surgery network. J Dtsch Dermatol Ges 2019; 17:1005.</a></li><li><a class="nounderline abstract_t">Lim JM, Oh Y, Lee SH, et al. Comparison of treatment options for small to medium congenital melanocytic nevi: A retrospective review of 119 cases. Lasers Surg Med 2019; 51:62.</a></li><li><a class="nounderline abstract_t">ALMutairi HM, Al-Hothali GI. The outcome of using different surgical modalities and laser therapy in the treatment of small- and medium-sized congenital melanocytic nevi: a systematic review. Int J Dermatol 2020; 59:535.</a></li><li><a class="nounderline abstract_t">Oh Y, Lee SH, Lim JM, et al. Long-term outcomes of laser treatment for congenital melanocytic nevi. J Am Acad Dermatol 2019; 80:523.</a></li><li><a class="nounderline abstract_t">Ponomarev IV, Topchiy SB, Pushkareva AE, et al. Treatment of Congenital Melanocytic Nevi With a Dual-Wavelengths Copper Vapor Laser: A Case Series. J Lasers Med Sci 2021; 12:e5.</a></li><li><a class="nounderline abstract_t">Kinsler V, Bulstrode N. The role of surgery in the management of congenital melanocytic naevi in children: a perspective from Great Ormond Street Hospital. J Plast Reconstr Aesthet Surg 2009; 62:595.</a></li><li><a class="nounderline abstract_t">Kinsler VA, Birley J, Atherton DJ. Great Ormond Street Hospital for Children Registry for Congenital Melanocytic Naevi: prospective study 1988-2007. Part 2--Evaluation of treatments. Br J Dermatol 2009; 160:387.</a></li><li><a class="nounderline abstract_t">Arad E, Zuker RM. The shifting paradigm in the management of giant congenital melanocytic nevi: review and clinical applications. Plast Reconstr Surg 2014; 133:367.</a></li><li><a class="nounderline abstract_t">Dragieva G, Hafner J, Künzi W, et al. Malignant melanoma in a large congenital melanocytic nevus 9 years after dermabrasion in childhood. Dermatology 2006; 212:208.</a></li><li><a class="nounderline abstract_t">Coughlin CC, Council ML, Gru AA, et al. Malignant melanoma arising at the site of a previously excised giant congenital melanocytic nevus. JAMA Dermatol 2014; 150:100.</a></li><li><a class="nounderline abstract_t">Adler N, Elia J, Billig A, Margulis A. Complications of nonbreast tissue expansion: 9 Years experience with 44 adult patients and 119 pediatric patients. J Pediatr Surg 2015; 50:1513.</a></li><li><a class="nounderline abstract_t">Margulis A, Billig A, Elia J, et al. Complications of Post-Burn Tissue Expansion Reconstruction: 9 Years Experience with 42 Pediatric and 26 Adult Patients. Isr Med Assoc J 2017; 19:100.</a></li><li><a class="nounderline abstract_t">Rhodes AR, Wood WC, Sober AJ, Mihm MC Jr. Nonepidermal origin of malignant melanoma associated with a giant congenital nevocellular nevus. Plast Reconstr Surg 1981; 67:782.</a></li><li><a class="nounderline abstract_t">Happle R. Speckled lentiginous naevus: which of the two disorders do you mean? Clin Exp Dermatol 2009; 34:133.</a></li><li><a class="nounderline abstract_t">Schaffer JV, Orlow SJ, Lazova R, Bolognia JL. Speckled lentiginous nevus: within the spectrum of congenital melanocytic nevi. Arch Dermatol 2001; 137:172.</a></li></ol></div><div id="topicVersionRevision">Topic 4847 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22497908" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7213564" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Epidemiology of congenital pigmented naevi: I. Incidence rates and relative frequencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15692463" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20541682" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Congenital melanocytic nevi-when to worry and how to treat: Facts and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16691193" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18032947" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18633438" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24129063" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23392294" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22982004" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : New recommendations for the categorization of cutaneous features of congenital melanocytic nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12130901" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Congenital melanocytic nevi: an update for the pediatrician.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28325390" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Patterns of distribution of giant congenital melanocytic nevi (GCMN): The 6B rule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23252411" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Dermoscopy for the pediatric dermatologist part III: dermoscopy of melanocytic lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17709659" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Age- and site-specific variation in the dermoscopic patterns of congenital melanocytic nevi: an aid to accurate classification and assessment of melanocytic nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16792752" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Instrument-, age- and site-dependent variations of dermoscopic patterns of congenital melanocytic naevi: a multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16707885" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Dermoscopic features of congenital melanocytic nevus and Becker nevus in an adult male population: an analysis with a 10-fold magnification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768479" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Dermoscopic characteristics of congenital melanocytic nevi affecting acral volar skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4756859" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Congenital melanocytic nevi of the small and garment type. Clinical, histologic, and ultrastructural studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6715623" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Precursors to malignant melanoma. National Institutes of Health Consensus Development Conference Statement, Oct. 24-26, 1983.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6715623" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Precursors to malignant melanoma. National Institutes of Health Consensus Development Conference Statement, Oct. 24-26, 1983.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22771898" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : High prevalence of angiotropism in congenital melanocytic nevi: an analysis of 53 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8543695" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Congenital nevomelanocytic nevi: proportionate area expansion during infancy and early childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1593350" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Giant pigmented nevi: clinical, histopathologic, and therapeutic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18280354" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Spontaneous involution of congenital melanocytic nevi of the scalp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24428471" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Images in clinical medicine. Halo phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19706090" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Meyerson phenomenon in children: observation in five cases of congenital melanocytic nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21436676" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28248717" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Mass Spectrometry Imaging Can Distinguish on a Proteomic Level Between Proliferative Nodules Within a Benign Congenital Nevus and Malignant Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16327602" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Risk of malignant transformation of congenital melanocytic nevi: a retrospective nationwide study from The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15253185" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Risk of melanoma arising in large congenital melanocytic nevi: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23182059" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Large congenital melanocytic nevi: therapeutic management and melanoma risk: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18811688" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Great Ormond Street Hospital for Children Registry for congenital melanocytic naevi: prospective study 1988-2007. Part 1-epidemiology, phenotype and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11252085" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Giant congenital melanocytic nevi: the significance of neurocutaneous melanosis in neurologically asymptomatic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35716834" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Central nervous system magnetic resonance imaging abnormalities and neurologic outcomes in pediatric patients with congenital nevi: A 10-year multi-institutional retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22980258" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Congenital melanocytic nevi: where are we now? Part I. Clinical presentation, epidemiology, pathogenesis, histology, malignant transformation, and neurocutaneous melanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22469364" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Spectrum of central nervous system abnormalities in neurocutaneous melanocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8859278" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Neurocutaneous melanosis: clinical features of large congenital melanocytic nevi in patients with manifest central nervous system melanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18671780" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Complications of congenital melanocytic naevi in children: analysis of 16 years' experience and clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19766348" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Large congenital melanocytic nevi and neurocutaneous melanocytosis: one pediatric center's experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14967788" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Number of satellite nevi as a correlate for neurocutaneous melanocytosis in patients with large congenital melanocytic nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11737677" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cerebral mass due to neurocutaneous melanosis: eight years later.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14576958" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Neurocutaneous melanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21672181" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Meeting report from the 2011 International Expert Meeting on Large Congenital Melanocytic Nevi and Neurocutaneous Melanocytosis, Tübingen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27872353" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Feed and Wrap MRI Technique in Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16310055" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Asymptomatic neurocutaneous melanocytosis in patients with large congenital melanocytic nevi: a study of cases from an Internet-based registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11803277" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Rhabdomyosarcoma arising in a congenital melanocytic nevus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22980259" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Congenital melanocytic nevi: where are we now? Part II. Treatment options and approach to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34845496" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Care of Congenital Melanocytic Nevi in Newborns and Infants: Review and Management Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31562702" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Multidisciplinary long-term care and modern surgical treatment of congenital melanocytic nevi - recommendations by the CMN surgery network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30375012" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Comparison of treatment options for small to medium congenital melanocytic nevi: A retrospective review of 119 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31792950" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The outcome of using different surgical modalities and laser therapy in the treatment of small- and medium-sized congenital melanocytic nevi: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30227194" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Long-term outcomes of laser treatment for congenital melanocytic nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34084731" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Treatment of Congenital Melanocytic Nevi With a Dual-Wavelengths Copper Vapor Laser: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19244003" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The role of surgery in the management of congenital melanocytic naevi in children: a perspective from Great Ormond Street Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19016692" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Great Ormond Street Hospital for Children Registry for Congenital Melanocytic Naevi: prospective study 1988-2007. Part 2--Evaluation of treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24469170" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The shifting paradigm in the management of giant congenital melanocytic nevi: review and clinical applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16484832" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Malignant melanoma in a large congenital melanocytic nevus 9 years after dermabrasion in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24284966" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Malignant melanoma arising at the site of a previously excised giant congenital melanocytic nevus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25891294" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Complications of nonbreast tissue expansion: 9 Years experience with 44 adult patients and 119 pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28457060" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Complications of Post-Burn Tissue Expansion Reconstruction: 9 Years Experience with 42 Pediatric and 26 Adult Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7243980" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Nonepidermal origin of malignant melanoma associated with a giant congenital nevocellular nevus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19040513" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Speckled lentiginous naevus: which of the two disorders do you mean?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11176689" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Speckled lentiginous nevus: within the spectrum of congenital melanocytic nevi.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
